OncoMatch/Clinical Trials/NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Is NCT05651932 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cohort A1 & A2: KTX-1001 and Cohort B1 & B2: KTX-1001+Mezigdomide for multiple myeloma.
Treatment: Cohort A1 & A2: KTX-1001 · Cohort B1 & B2: KTX-1001+Mezigdomide · Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) · Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) — A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: MMSET t(4;14)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
≥ 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody
Must have received: immunomodulatory drug
≥ 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody
Must have received: anti-CD38 antibody
≥ 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody
Cannot have received: mezigdomide
Exception: Cohorts B1 and B2 only
Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment
Cannot have received: carfilzomib (carfilzomib)
Exception: immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2
Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2
Cannot have received: pomalidomide (pomalidomide)
Exception: immediate last prior line of therapy for patients enrolled in cohort D
Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D
Cannot have received: radiation therapy
Exception: ≤ 2 weeks
Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks
Cannot have received: cytotoxic chemotherapy
Exception: ≤ 2 weeks
Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks
Cannot have received: immunotherapy
Exception: ≤ 2 weeks
Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks
Cannot have received: cellular therapy
Exception: ≤ 8 weeks
Cellular therapies ≤ 8 weeks
Cannot have received: autologous transplant
Exception: < 100 days
Autologous transplant < 100 days
Cannot have received: allogenic transplant
Exception: ≤ 6 months, or > 6 months with active GVHD
Allogenic transplant ≤ 6 months, or > 6 months with active GVHD
Lab requirements
Blood counts
Inadequate bone marrow function [excluded]
Kidney function
Inadequate renal function [excluded]
Liver function
Inadequate hepatic function [excluded]
Cardiac function
Inadequate cardiac function [excluded]
Inadequate bone marrow function; Inadequate renal, hepatic, pulmonary, and cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic · San Francisco, California
- Mayo Clinic Hospital - Florida · Jacksonville, Florida
- The Winship Cancer Institute of Emory University · Atlanta, Georgia
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify